Milestones

Defining years

1984

In 1984, Granules India was formed as Triton Laboratories to produce Paracetamol API at our Bonthapally facility in Hyderabad.

1987

In 1987, Triton became the second Indian company to export pharmaceutical products to the U.S.

1990

In 1990, Triton opened its second manufacturing facility at Jeedimetla to produce multiple APIs.

1991

In 1991, Triton laboratories was incorporated into Granules India Limited.

1993

In 1993, Granules establishedits first PFI facility at Jeedimetla.

1995

In 1995, Granules became a public company, after having initial public offerings on the Bombay and Hyderabad Stock Exchanges.

2003

In 2003, Granules opened a new large volume PFI facility in Gagillapur.

2003

In 2003, Granules setup a wholly owned subsidiary, Granules USA, for marketing in the US

2005

In 2005, a new Paracetamol plant was built in Bonthapally, Hyderabad.

2006

In 2006, Granules formed a joint venture with Hubei Biocause to make and sell Ibuprofen API.

2008

In 2008, Granules entered into the Finished Dosage segment.

2010

In 2010, Granules received US FDA approval for its first Abbreviated New Drug Application (ANDA).

2011

In 2011, Granules-OmniChem, a joint venture with Ajinomoto OmniChem was established to venture into Contract Research and Manufacturing Services (CRAMS) business.

2013

In 2013, Granules established a 10,000 sq. foot R&D facility in Pragathi Nagar, Hyderabad.

2014

In 2014, Granules acquired Auctus Pharma

2014

In 2014, Granules setup a wholly-owned subsidiary in the US; Granules Pharmaceutical to focus on formulation R&D.


  • Regulatory approvals are for the plants/ facilities
  • Products only include commercial products and no intermediates
  • Employees only include staff on the payroll

2015

In 2015, Granules entered the Over the Counter business in the US through Granules Consumer Healthcare.

2016